June 25, 2026 06:30 pm (IST)
Follow us:
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi
Thu, Jun 25 2026
Rajesh Exports crashes 5%! ED probe triggers fresh investor panic
Thu, Jun 25 2026
Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners
Thu, Jun 25 2026
Decentralizing Spending Without Losing Control - A Leader's Approach to Modern Expense Governance
Thu, Jun 25 2026
Adani stocks soar! Investors rush in after Gautam Adani unveils massive Rs 2 lakh crore expansion plan
Wed, Jun 24 2026